Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Leah J. Salituro
Observed names:
L. Salituro,
Leah Salituro
Institution:
Cogent Biosciences (United States)
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
University of California, Irvine,
Cogent Biosciences (United States),
Connecticut College
ORCID:
0000-0002-6359-354X
Observed ORCID:
0000-0002-6359-354X
OpenAlex ID:
A5004736204
Enabling Photoactivated Cross-Linking Mass Spectrometric Analysis of Protein Complexes by Novel MS-Cleavable Cross-Linkers
2021
·
Craig Gutierrez
, Leah J. Salituro
, et al.
·
Molecular & Cellular Proteomics
·
37
PDF
Total Syntheses of Strasseriolide A and B, Antimalarial Macrolide Natural Products
2022
·
Leah J. Salituro
, Jessica E. Pazienza
, et al.
·
Organic Letters
·
25
Exploring an Alternative Cysteine-Reactive Chemistry to Enable Proteome-Wide PPI Analysis by Cross-Linking Mass Spectrometry
2023
·
Fenglong Jiao
, Leah J. Salituro
, et al.
·
Analytical Chemistry
·
19
PDF
Assessment of coulometric array electrochemical detection coupled with HPLC-UV for the absolute quantitation of pharmaceuticals
2017
·
Michael B. Hicks
, Leah Salituro
, et al.
·
The Analyst
·
10
Cloning of the Blue Ghost (Phausis reticulata) Luciferase Reveals a Glowing Source of Green Light
2016
·
Bruce R. Branchini
, Tara L. Southworth
, et al.
·
Photochemistry and Photobiology
·
10
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
2025
·
Aaron C. Smith
, Ben Arwood-Levine
, et al.
·
Cancer Research
·
1
Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.
2026
·
John Fischer
, Kim Alley
, et al.
·
Cancer Research
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
2025
·
Mark Chicarelli
, Michelle Crow
, et al.
·
Blood
PDF
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS
2025
·
John Fischer
, Kim Alley
, et al.
·
Molecular Cancer Therapeutics
Abstract P4-12-19: Preclinical Characterization of a Novel PI3Kα H1047R Mutant-Selective Inhibitor
2025
·
Aaron C. Smith
, Ben Arwood-Levine
, et al.
·
Clinical Cancer Research
Abstract 6974: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRAS
2025
·
Keith Koch
, Kim Alley
, et al.
·
Cancer Research
120 (PB108): Identification of a Potent KRAS Dual On/Off Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS
2024
·
J. Fischer
, K. Alley
, et al.
·
European Journal of Cancer
Abstract PO3-26-01: Preclinical in vitro and in vivo characterization of a novel, wild-type-sparing, PI3Kα H1047R mutant-selective inhibitor
2024
·
Aaron C. Smith
, Ben Arwood-Levine
, et al.
·
Cancer Research
Synthesis and Characterization of a Novel Near-Infrared Luciferin
2017
·
Leah J. Salituro
·
Digital Commons @ Connecticut College (Connecticut College)
University of Otaga, Chemistry Department
2016
·
Leah J. Salituro
·
Digital Commons @ Connecticut College (Connecticut College)
Show more works
View as search
Works count:
15
Citation count:
102
H-index:
5
I10-index:
5
Year
Topic
Type
